OCUPATCH TM
OcupatchTM is a novel drug delivery system designed to deliver drug to ocular tissues via percutaneous permeation from patch applied to eyelid directly. Since OcupatchTM may allow for more controlled concentrations of drug in the ocular tissues, thus providing a more effective and safer treatment than the existing ophthalmic product such as eye drops ophthalmic ointment etc. Since OcupatchTM is not aqueous based, preservatives are not necessary in the patch.
Benefit of Ocupatch TM compared to eyedrops
- No eye drops will be needed during daytime, given OcupatchTM can introduce sufficient drug to target tissues during sleeping.
- As OcupatchTM does not have preservatives, contact lenses could be left in during patch use. Therefore, OcupatchTM is not anticipated to induce the corneal toxicity by preservatives.
- Children and elderly patients who can’t easily self-administer eye drops may have significant clinical benefit from OcupatchTM.
SNFL
OPHTHALMIC COMPOSITION: US Patent US8211450.
OPHTHALMIC COMPOSITION: WO/2011/140194.
ARVO 2012: Enhanced Ocular Bioavailability of Carbonic Anhydrase Inhibitor Formulation with Novel Nanopolymers.
Increase in solubility of Dorzolamide with increase in Hyperbranched polymer (HP) concentration at pH 7
Increase in cornea permeability of Dorzolamide with increase in HP
ISER 2012: Enhanced Ocular Bioavailability of Carbonic Anhydrase Inhibitor Formulation with Novel Hyperbranched Polyesters
Increase in solubility of Dorzolamide with increase in HP concentration at pH 7
Increase in cornea permeability of Dorzolamide and Timolol with increase in HP.
